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In Brief
Dysregulated PI3K signaling is
associatedwithmany disease processes.
Chu et al. now find that an unconventional
signaling pathway, PI3Kb/d-Cdc42-Pak-
Mek-Erk, regulates immune-complex-
induced apoptosis in human neutrophils.
This non-canonical PI3K signaling
pathway, which is not conserved in the
mouse, may affect the resolution of
inflammation in humans.
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Neutrophils are peripheral blood leukocytes that
represent the first line of immune cell defense against
bacterial and fungal infections but are also crucial
players in the generation of the inflammatory
response. Many neutrophil cell surface receptors
regulate important cellular processes via activation
of agonist-activatedPI3Ks.We showhere that activa-
tionofhumanneutrophilswith insoluble immunecom-
plexes drives a previously uncharacterized, PI3K-
dependent, non-canonical, pro-apoptotic signaling
pathway, FcgR-PI3Kb/d-Cdc42-Pak-Mek-Erk. This
is a rare demonstration of Ras/Raf-independent acti-
vation of Erk and of PI3K-mediated activation of
Cdc42. In addition, comparative analysis of immune-
complex- and fMLF-induced signaling uncovers key
differences in pathways used by human and murine
neutrophils. The non-canonical pathway we identify
in this study may be important for the resolution of
inflammation in chronic inflammatory diseases that
rely on immune-complex-drivenneutrophil activation.
INTRODUCTION
Neutrophils, the most abundant circulating leukocytes in hu-
mans, represent the first line of immune cell defense against bac-
terial and fungal infections. Neutrophils are also a key component
of the inflammatory response (Nathan, 2006; Nauseef and Borre-
gaard, 2014). Activated neutrophils leave the bloodstream to
migrate to sites of infection or sterile insult. However, uncon-
trolled neutrophil activation can contribute to significant host tis-
sue damage, as evidenced in a number of chronic inflammatory
diseases such as rheumatoid arthritis and proliferative glomeru-
lonephritis. Neutrophils are terminally differentiated, short-lived
cells that are programmed to undergo apoptosis. Plasma mem-
brane alterations associated with neutrophil apoptosis trigger
phagocytic clearancebymacrophages. This prevents the release
of pro-inflammatory cell debris as a consequence of secondary
necrosis, limiting host damage, and is crucial for the resolution
of inflammation (Michlewska et al., 2007; Poon et al., 2014).374 Cell Reports 17, 374–386, October 4, 2016 ª 2016 The Authors.
This is an open access article under the CC BY license (http://creativeNeutrophils are activated by a variety of extracellular stimuli,
including formylated bacterial peptides and immune complexes,
that bind specific cell surface receptors. This induces intracellular
signaling cascades that initiate tightly controlled effector func-
tions. Immune complexes are important mediators of neutrophil
recruitment and neutrophil-dependent tissue damage in many
inflammatory diseases, including rheumatoid arthritis, systemic
lupus erythematosus, andproliferative glomerulonephritis (Maya-
das et al., 2009). Immune complexes activate neutrophils and
induce a range of effector functions, including the formation of
reactive oxygen species (ROS), degranulation and cytokine pro-
duction, as well as neutrophil apoptosis (Fossati et al., 2002b;
Gamberale et al., 1998; Ottonello et al., 2001; Schettini et al.,
2002). Neutrophils bind soluble and insoluble as well as immobi-
lized immune complexes via their immunoglobulin G (IgG) Fc
receptors (FcgRs). FcgR ligation induces intracellular signaling,
with receptor proximal events including activation of Src/Syk
kinases and several key downstream signaling pathways,
including protein kinase C, phospholipase Cg, and agonist-acti-
vated phosphoinositide 3-kinases (PI3Ks) (van Rees et al., 2016).
Agonist-activated PI3Ks are key regulators of cellular signaling
that are involved downstream of many cell surface receptors,
including FcgRs. Because dysregulated PI3K signaling is
associated with many diseases, including neutrophil-dependent
chronic inflammatory conditions, PI3K signaling is the focus of
both basic research and drug discovery programs. Four isoforms
are known, PI3Ka, b, g, and d, all of which are expressed by
the neutrophil. Following activation, agonist-activated PI3Ks pro-
duce the lipid second messenger phosphatidylinositol (3,4,5)-
trisphosphate (PIP3) by phosphorylating the plasma mem-
brane component phosphatidylinositol (4,5)-bisphosphate. In
the neutrophil as elsewhere, PI3Ks signal through multiple down-
stream effectors to regulate numerous aspects of neutrophil
biology (Hawkins et al., 2010). Despite this, the analysis of PI3K
signaling has often focused on the best-characterized PI3K
effector, Akt (also known as protein kinase B [PKB]), and indeed,
Akt phosphorylation is often used as a readout of PI3K activity.
The present project set out to characterize signaling processes
downstream of agonist-activated PI3Ks in the neutrophil. Using
a combination of pharmacological inhibition, activity assays, and
functional assays, we identified a non-canonical pathway, PI3K-
Cdc42-Pak-Mek-Erk that operates in immune-complex-stimu-
latedhumanneutrophils. Thispathway ispro-apoptotic, regulatingcommons.org/licenses/by/4.0/).
Figure 1. Erk Is Activated Downstream of
PI3K in iIC-Stimulated Neutrophils
(A–J) Peripheral blood-derived healthy donor
neutrophils (A–C andG–J) or bonemarrow-derived
mouse neutrophils (D–F) were pre-incubated with
PI3K inhibitors (wortmannin, pan-PI3K; TGX221,
PI3Kb-selective; IC87114, PI3Kd-selective) or
vehicle at 37C for 10 min as indicated prior to
stimulation with 10 mg/mL iIC (HSAaHSA) or buffer
for 10 min (A–F) or the indicated time points (G–J).
To terminate the assay, cells were pelleted, fol-
lowed by resuspension in ice-cold lysis buffer.
Soluble protein was subjected to SDS-PAGE and
western blotting to detect specific phosphorylation
events or b-actin as a loading control as indicated.
Representative examples are shown together with
densitometry data integrated from a minimum of
three separately conducted experiments. For ease
of viewing, the data shown are normalized to the
activated control. Error bars show SEM. *p < 0.05,
**p < 0.01. See also Figure S1.the ratio of the Bcl-2 family members Mcl-1 and Bax. The pre-
sent work furthermore uncovered significant differences between
signaling pathways employed by human and mouse neutrophils.
RESULTS
PI3K Lies Upstream of Erk in Immune-Complex-
Stimulated Human and Mouse Neutrophils
We stimulated human and mouse neutrophils with insoluble
immune complexes (iICs) and observed significant PI3K (asCelldetermined by Akt phosphorylation) as
well as Erk and p38 mitogen-activated
protein kinase (MAPK) activation. Interest-
ingly, Erk but not p38 MAPK activation
was completely PI3K-dependent in both
mouse and human neutrophils, as indi-
cated by the use of the pan-PI3K inhibitors
wortmannin (Figures 1A–1F) or LY294002
(data not shown). PI3K-dependent Erk
activation was also observed with neutro-
phils that had been stimulated by being
plated onto integrin ligands or onto immo-
bilized immune complexes (Figure S1).
Comparison of the roles of PI3Kb and d in
immune-complex-activated human neu-
trophils revealed that, in contrast tomouse
neutrophils (Kulkarni et al., 2011), PI3Kd
rather than PI3Kb made the major contri-
bution (Figures 1A–1F).
Akt is known to be regulated by PI3K
in two ways: directly, via PDK1-depen-
dent phosphorylation of Thr 308 (Alessi
et al., 1997; Stephens et al., 1998), and
also indirectly, via mTORC2-dependent
phosphorylation of Ser 473 (Sarbassov
et al., 2005). We next examined thetiming of Erk phosphorylation with that of both phosphorylation
sites on Akt. Thr 308 phosphorylation of Akt occurred within
15 s of stimulation of neutrophils with iICs, whereas Ser 473
phosphorylation was detectable only after 10 min, peaking
30 min after stimulation. In contrast, phosphorylation of Erk1/
2 on Thr 202 and Tyr 204 became apparent at 5 min and
peaked 10 min after iIC stimulation (Figures 1G–1J). Thus,
PI3K-dependent Erk stimulation was an indirect event that
was regulated independently of PI3K-mediated phosphoryla-
tion of Akt.Reports 17, 374–386, October 4, 2016 375
PI3K-Dependent Erk Activation of Human Neutrophils
Involves Mek but Not Ras or Raf
Our observation of PI3K-dependent Erk activation was unex-
pected because activation of Erk usually follows the canonical
Ras-Raf-Mek-Erk cascade. We therefore sought to further
characterize this pathway. Ras is known to activate PI3Ka, d,
and g but not b (Burke and Williams, 2015), although, under
certain conditions, PI3K has been demonstrated to lie upstream
of Ras (Wennstro¨m and Downward, 1999). Because no specific
Ras inhibitors have been reported yet, we examined Ras activity
in iIC-stimulated neutrophils in the presence or absence of
wortmannin to test whether PI3K might lie upstream of Ras in
iIC-stimulated neutrophils. iICs drove substantial activation of
Ras, which was not affected by inhibition of PI3K (Figure 2A),
in line with the notion that Ras is activated independently or
indeed upstream of PI3K following FcgR stimulation.
We next tested the involvement of Raf upstream of Erk by
making use of a covalent Raf inhibitor, AZ628 (Hatzivassiliou
et al., 2010). In these assays, Raf inhibition had no effect on
Akt and Erk (or Mek) phosphorylation of iIC-stimulated neutro-
phils (Figures 2B–2E). Because these results were unexpected,
we undertook a comparative analysis of fMet-Leu-Phe (fMLF)-
stimulated human neutrophils, where Erk activation was inde-
pendent of PI3K (Figures 2F–2H). In contrast to the effects of
Raf inhibition on iIC-mediated signaling, Erk and Mek (but not
Akt) activation in fMLF-stimulated human neutrophils was atten-
uated (Figures 2I–2L).
To test the involvement of Mek upstream of Erk, we pre-
treated neutrophils with twoMek inhibitors: AZD6244 and trame-
tinib/GSK1120212 (Abe et al., 2011; Yeh et al., 2007), before
stimulating them with iICs. Mek inhibition with either of these
compounds abolished Mek and Erk but not Akt activation (Fig-
ures 2M–2P), in line with the notion that Erk phosphorylation
was Mek-dependent. We concluded that PI3K-dependent acti-
vation of Erk in iIC-stimulated human neutrophils followed a
non-canonical pathway that involves Mek but not Raf or Ras.
PI3KSignaling PathwaysArePoorly Conserved between
Human and Mouse Neutrophils
We next examined which signaling pathways were operating in
iIC-stimulated mouse neutrophils. We found that, as for human
neutrophils, Erk but not Akt phosphorylation was abolished by
inhibiting Mek (Figures 3A–3C). However, inhibition of Raf in
mouse neutrophils caused partial Erk inhibition (Figures 3D–
3F), suggesting that, although PI3K lies upstream of Erk in iIC-
stimulated human and mouse neutrophils, different pathways
operate in the two organisms.
In support of our suggestion that there is differential signaling
in human and mouse neutrophils, analysis of fMLF-stimulated
mouse neutrophils revealed that Erk but not p38 MAPK activa-
tion was completely PI3K-dependent, further contrasting the sit-
uation in human neutrophils. Use of isoform-specific inhibitors,
including the PI3Kg-selective AS252424 (Pomel et al., 2006)
and CZC24832 (Bergamini et al., 2012), suggested that this
was due to PI3Kg (Figures 3G–3I). Moreover, although inhibiting
Mek abolished Erk (but not Akt) activation (data not shown), in-
hibiting Raf in fMLF-stimulated mouse neutrophils reproducibly
caused partial Erk inhibition (data not shown).376 Cell Reports 17, 374–386, October 4, 2016PI3K Regulates Erk via Non-canonical Pak Signaling
We next sought to define the involvement of alternative Mek ki-
nases. p21-activated kinase (Pak) has been demonstrated to
function as a Mek kinase in a number of contexts, including in
myeloid cells (Eblen et al., 2002; Smith et al., 2008). In our exper-
iments with human neutrophils, Pak was phosphorylated in a
PI3K-dependent fashion on Ser 144 following stimulation with
iICs (Figures 4A and 4C), in line with a stimulatory Pak autophos-
phorylation event (Chong et al., 2001). We further tested Pak’s
potential involvement by using a pan-Pak inhibitor, PF3758309
(Zhao and Manser, 2010), and a Pak1-3 inhibitor, IPA3 (Deacon
et al., 2008). Both compounds significantly inhibited Mek and
Erk (but not Akt) activation in human neutrophils that had been
stimulated with iICs (Figures 4A–4E).
We tested the Pak inhibitors and Pak phosphorylation with
mouse neutrophils that had been stimulated with iICs. Pak
inhibition did not interfere with Akt or indeed Erk activation in
iIC-stimulated mouse neutrophils (Figures 4F–4H) or indeed
those stimulatedwith fMLF (data not shown).We did not observe
any Pak autophosphorylation on stimulation of mouse neutro-
phils with iICs (data not shown). These results suggested an
involvement of Pak as MAP kinase kinase kinase (MAP3K) in
iIC-activated neutrophils downstream of PI3K in human but not
mouse neutrophils. Taken together, our data suggest that
signaling pathways downstream of PI3K are poorly conserved
between mouse and human neutrophils. In view of these differ-
ences between signaling pathways engaged in mouse and hu-
man neutrophils, we decided to concentrate on iIC-induced
signaling in human cells for the remainder of this study.
Cdc42 but Not Rac Is Activated in a PI3K-Dependent
Fashion in iIC-Stimulated Human Neutrophils
Paks can be activated by Rac and Cdc42 (Bokoch, 2003). In the
absence of convincing inhibitors for Rho family small GTPases,
we determined the effect of PI3K inhibition with wortmannin
upon Rho family activity in human neutrophils stimulated with
iICs. The link between PI3K and Rac is well established, with
several phosphatidyl-inositol-(3,4,5)-trisphosphate (PtdIns(3,4,5)
P3)-activated Rac guanine nucleotide exchange factors (GEFs)
described and shown to be functional in neutrophils (Dong et al.,
2005; Kunisaki et al., 2006; Welch et al., 2002, 2005). Although
iICs stimulated Rac in neutrophils, to our surprise, inhibition of
PI3K did not reduce Rac activation in this context (Figure 5A).
This contrasted the situation with fMLF-stimulated neutrophils,
where Rac activation was dependent on PI3K (Figure 5B), in
line with published observations (Welch et al., 2005). There is
little evidence for PI3K-mediated regulation of Cdc42, and no
PtdIns(3,4,5)P3-regulatedCdc42GEFshavebeendescribed (Ver-
merenet al., 2009).Our experiments showed thatCdc42, likeRac,
was activated in iIC-stimulated neutrophils and that Cdc42
activation was significantly reduced in neutrophils that had been
pre-incubatedwithwortmannin (Figure5C).Again, this contrasted
our findings with fMLF-stimulated neutrophils, where, as ex-
pected, Cdc42 activation was PI3K independent (Figure 5D). We
concluded from these experiments, that Cdc42 rather than Rac
is regulated by PI3K in iIC-stimulated neutrophils and assumed
that Cdc42, not Rac, is a likely regulator of Pak in iIC-stimulated
human neutrophils.
Figure 2. Erk Lies Downstream of Mek but Not Raf or Ras in iIC-Stimulated Human Neutrophils
(A–P) Peripheral blood derived healthy donor neutrophils were pre-incubated with small-molecule inhibitors (AZ628, Raf-specific; AZD6244 and tramatinib, Mek-
specific) or vehicle at 37C for 10 min as indicated prior to 10-min stimulation with 10 mg/mL iIC (HSAaHSA) (A, B–E, and M–P) or 60-s stimulation with 100 nM
fMLF (F–L). To terminate the assay, cells were pelleted, followed by resuspension in ice-cold lysis buffer. Soluble cellular protein was subjected to (A) analysis of
guanosine triphosphate (GTP)-Ras by G-LISA assay or (B–P) SDS-PAGE and western blotting to detect specific phosphorylation events or b-actin or b-COP as a
loading control as indicated. Representative blots are shown (B, F, I, and M) together with densitometry data integrated from a minimum of three separately
conducted experiments. For ease of viewing, the data shown are normalized to the activated control. Error bars show SEM. The dotted lines in (B) and (I) indicate
where lanes derived from the same blot were pasted next to one another for ease of viewing. NS, not significant. **p < 0.01, ***p < 0.001.
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Figure 3. PI3K Signaling Is Not Conserved in Human and Mouse Neutrophils
(A–I) Bone marrow-derived mouse neutrophils were pre-incubated with small-molecule inhibitors (Wortmannin, pan-PI3K; TGX221, PI3Kb; IC87114, PI3Kd;
AZD6244, Mek; A66, PI3Ka; AS252424 and CZC24832, PI3Kg; AZ628, Raf) or vehicle at 37C for 10 min as indicated prior to stimulation with 10 mg/mL iIC
(HSAaHSA) (A–F), 1 mM fMLF (G–I), or vehicle. To terminate the assay, cells were pelleted, followed by resuspension in ice-cold lysis buffer. Soluble cellular
protein was subjected to SDS-PAGE and western blotting to detect specific phosphorylation events or b-actin or b-COP as loading controls as indicated.
Representative examples are shown together with densitometry data integrated from aminimumof three separately conducted experiments. For ease of viewing,
the data shown are normalized to the activated control. (H) and (I) include an additional PI3Kg inhibitor, CZC24832, which had not been included in the example
shown in (G). Error bars show SEM. *p < 0.05, **p < 0.01, ***p < 0.001.PI3Kb/d-Activated Erk Signaling Regulates Neutrophil
Apoptosis
iICs are known to trigger a number of functions in neutrophils, one
ofwhich is the induction of neutrophil apoptosis (Gamberale et al.,378 Cell Reports 17, 374–386, October 4, 20161998; Ottonello et al., 2001; Schettini et al., 2002). We therefore
determined whether this unconventional signaling pathway regu-
lates apoptosis. In linewith published observations,we found that
iIC-treated neutrophils exhibited accelerated apoptosis, with
Figure 4. Human but NotMouseNeutrophils
Use Pak as Mek Kinase following iIC Stimu-
lation
(A–H) Peripheral blood-derived healthy donor
neutrophils (A–E) and bonemarrow-derivedmouse
neutrophils (F–H) were pre-incubated with in-
hibitors (PF3758309 and IPA3, Pak inhibitors) or
vehicle at 37C for 10 min as indicated prior to
stimulation with 10 mg/mL iICs (HSAaHSA) or
vehicle. To terminate the assay, cells were pel-
leted, followed by resuspension in ice-cold lysis
buffer. Soluble cellular protein was subjected to
SDS-PAGE and western blotting to detect specific
phosphorylation events or b-actin as a loading
control as indicated. Representative examples are
shown together with densitometry data integrated
from a minimum of three separately conducted
experiments. For ease of viewing, the data shown
are normalized to the activated control, and error
bars show SEM. Note that the additional Pak in-
hibitor IPA3 shown in (B)–(E) was not included in
the example shown in (A). *p < 0.05, **p < 0.01.more than 50% of neutrophils undergoing apoptosis at 12 hr
comparedwithapproximately25%ofvehicle-treatedneutrophils.
Inclusion of inhibitors directed against PI3Ks, Pak, Mek, and Erk
(FR180204) significantly reduced the extent towhich iICs induced
apoptosis (Figure 6A) and also secondary necrosis, as evaluated
by flow cytometry and according to cytocentrifuge preparations
(Figure S2). The inhibitors did not affect the extent of apoptosis
in cells that had not been stimulated with iICs (Figure S2), demon-
strating that this signaling pathway operates specifically following
activation of neutrophils through their FcgRs.
Neutrophil apoptosis is known to be regulated by fine-tuning
levels of Bcl-2 family proteins, where, in neutrophils, the pro-
survival member Mcl-1 and the pro-apoptotic Bax are particu-
larly important (Duffin et al., 2010; Murphy and Caraher, 2015).
Stimulating neutrophils with iICs induced Bax expression, in
agreement with an earlier report (Ottonello et al., 2001), and
it also induced Mcl-1 (Figure 6B). Inhibitor treatment did not
affect Bax levels but further increasedMcl-1 expression, therebyCellaltering the ratio of Mcl-1 to Bax
and delaying the induction of apoptosis
(Figure 6C).
PI3Kb/d Regulates Further
Neutrophil Functions through
Alternative Pathways
We next determined whether the uncon-
ventional signaling pathway also regu-
lates other neutrophil functions, concen-
trating on ROS production, cytokine
release, and L-selectin shedding.
Stimulation of human neutrophils with
iICs has been shown to stimulate the gen-
eration of intracellular ROS (Crockett-Tor-
abi and Fantone, 1990; Fossati et al.,
2002a), and iIC-induced ROS generation
was shown to be required for the induc-tion of apoptosis (Gamberale et al., 1998). In our hands, iICs
drove significant production of internal ROS over an extended
period of time (see Figure 7A for an example). Inhibition of
PI3K using LY294002 attenuated iIC-induced ROS production.
In keeping with the biochemical analysis shown in Figure 1,
PI3Kdwasmore critical than PI3Kb for iIC-induced ROS produc-
tion by human neutrophils (Figure 7A). To test whether PI3K reg-
ulates ROS production through the unusual pathway described
in this work, we also pre-incubated neutrophils with Erk, Mek,
and Pak inhibitors prior to analyzing ROS production. We used
an alternative Erk inhibitor, BVD523 (Hayes et al., 2016) for this
because the bright yellow color of FR180204 interfered with
the assay (Figure S4). Inhibitors other than those for PI3K did
not affect ROS production (Figure 7B).
Many physiological stimuli induce the production of inflamma-
tory cytokines and chemokines by neutrophils to recruit immune
cells to sites of inflammation and to regulate cross-talk between
immune cells (Scapini et al., 2000). We noticed that stimulation ofReports 17, 374–386, October 4, 2016 379
Figure 5. Cdc42 but Not Rac Is Activated in a PI3K-Dependent Fashion in iIC-Stimulated Human Neutrophils
(A–D) Peripheral blood-derived healthy donor neutrophils were pre-incubated with the pan-PI3K inhibitor wortmannin or vehicle at 37C for 10 min as indicated
prior to stimulation with 10 mg/mL iICs (A and C), 100 nM fMLF (B and D), or buffer. To terminate the assay, cells were pelleted, followed by resuspension in ice-
cold lysis buffer. Soluble cellular protein was subjected to G-LISA assay to detect GTP-Rac (A and B) and GTP-Cdc42 (C and D). Data from at least four separate
experiments were integrated for the graphs shown. Error bars show SEM. NS, not significant; *p < 0.05, **p < 0.01.human neutrophils with iIC triggered strong IL-8 release (Fig-
ure 7C) but were unable to detect any tumor necrosis factor a
(TNF-a) release (data not shown). iIC-induced IL-8 release was
significantly reduced on pre-incubating the neutrophils with the
pan-PI3K inhibitor LY294002 and when inhibiting PI3Kb/d but
not Pak, Mek, or Erk (Figure 7C).
Finally we interrogated iIC-mediated L-selectin (CD62L) shed-
ding, a sensitive indicator of neutrophil activation that is due to
the rapid proteolytic cleavage of neutrophil L-selectin following
a variety of stimuli. iICs induced efficient L-selectin shedding
that was found to be dependent on PI3Kb/d but not on Pak,
Mek, or Erk (Figure 7D). In conclusion, iICs drive multiple neutro-
phil functions that are regulated by PI3Kb/d-dependent path-
ways that diverge from the non-canonical pathways we have
demonstrated to regulate apoptosis. These observations are in
line with the notion that, on ligation of FcgR receptors, PI3K reg-
ulates diverse neutrophil functions by signaling through several
different effector proteins (Figure 7E).
DISCUSSION
This work has unearthed an unorthodox signaling pathway that
controls immune-complex-induced apoptosis in human neutro-
phils. Rather than employing the canonical and well character-
ized Ras-Raf-Mek-Erk module, our work demonstrates that an
alternative PI3Kb/d-Cdc42-Pak-MekErk axis operates in iIC-
stimulated human neutrophils (Figure 7). The present work was
carried out under defined situations in vitro with neutrophils pu-
rified from the peripheral blood of healthy donors. It would be
interesting to test whether the pathway that we have identified
is also utilized under conditions that might be encountered by
neutrophils at inflammatory sites in vivo. It is likely that the pro-
cess of extravasation and the complex mixture of inflammatory
cytokines and chemokines present at these sites prime and/or
activate neutrophils, which may alter intracellular signaling path-
ways that are engaged.
PI3K regulates Erk activation in iIC-stimulated human and
mouse neutrophils. As with human neutrophils, iIC stimulation
drives PI3Kb/d-dependent apoptosis of mouse neutrophils
(data not shown). We provide evidence that, although Pak acts
as the MAP3K in human neutrophils, this is not the case in the380 Cell Reports 17, 374–386, October 4, 2016mouse. Our data also indicate that signaling is not well
conserved between fMLF-stimulated human and mouse
neutrophils. Our findings are in line with a previous report that
demonstrated differential usage of PI3K isoforms during ROS
production by fMLF-stimulated human and mouse neutrophils
(Condliffe et al., 2005). In the present work, we prepared human
neutrophils from peripheral blood, whereas mouse neutrophils
were derived from bone marrow preparations. Use of mouse
bone marrow is common practice because it permits obtaining
adequate numbers of cells for experiments. It is conceivable
that the differences observed between human and murine neu-
trophils reflect a difference in the maturity of the cells. However,
although human bone marrow-derived neutrophils have been
shown to be functionally immature (Cowland and Borregaard,
1999), mouse bone marrow is reported to contain a large reser-
voir of functionally mature, readily primed neutrophils with regard
to morphology and effector functions (Boxio et al., 2004; Itou
et al., 2006). Our findings raise the possibility that there are
genuine differences between signaling pathways used bymouse
and human neutrophils. Primary human neutrophils can easily be
prepared from peripheral blood but are not amenable to culture,
transfection, or indeed transduction, restricting investigators to
the use of inhibitors and functional assays. In allowing access
to genetic manipulation and in vivo models, mice represent a
very attractive alternative for neutrophil biology. The lack of con-
servation of signaling pathways between human and mouse
coupled with the terminal differentiated and short-lived nature
of neutrophils precludes any genetic analysis of the unconven-
tional signaling that we describe for human cells. In addition,
our observations, together with those of others, argue that novel
insights gained with mouse models may need to be tested for
their validity in human cells.
We identified Pak to act as anMAP3K in iIC-stimulated human
neutrophils. Pak has been shown to act as an MAP3K in some
circumstances, including in myeloid cells (Eblen et al., 2002;
Smith et al., 2008). Interestingly, we observed Mek to be phos-
phorylated on Ser 217/Ser 221 in a Pak-dependent fashion
(Figures 4A and 4D). These residues correspond to the Raf phos-
phorylation sites, with Pak reported to phosphorylateMek on Ser
298 (Slack-Davis et al., 2003). Ser 293 phosphorylation has been
proposed to sensitize Mek to Raf-dependent phosphorylation
Figure 6. PI3K-Cdc42-Pak-Mek-Erk Signaling Regulates iIC-
Induced Neutrophil Apoptosis
Peripheral blood-derived healthy donor neutrophils were prepared and pre-
incubated with small-molecule inhibitors (LY294002, stable pan-PI3K in-
hibitor; TGX221, PI3Kb; IC87114, PI3Kd; PF3758309, Pak; tramatinib, Mek;
FR180204, Erk) or vehicle at 37C for 10 min as indicated prior to stimulation
with 10 mg/mL iICs or buffer.
(A) Cells were cultured for 12 hr in Iscove’s Modified Dulbecco’s Medium
(IMDM) supplemented with 10% autologous serum in a humidified, CO2
controlled incubator prior to staining with annexin V and propidium iodide for
analysis by flow cytometry. Double-negative cells were defined as viable,
annexin V-positive and propidium iodide-negative cells as apoptotic, and
double-positive cells as necrotic. The same trends were observed with cells
that had been cultured in PBS2+ instead of culture medium.
(B) Following 3-hr culture in PBS2+, cells were pelleted, followed by re-
suspension in ice-cold lysis buffer. Soluble cellular protein was subjected to
SDS-PAGE and western blotting to detect cellular Mcl-1 and Bax. A repre-
sentative example is shown together with densitometry data integrated from a
minimum of three separately conducted experiments.
(C) The data shown are normalized to b-actin expression for ease of viewing.
(A and C) The data shown are integrated from a minimum of three separately
conducted experiments.
Error bars show SEM. *p < 0.05, **p < 0.01. See also Figures S2 and S3.(Coles and Shaw, 2002; Frost et al., 1997). An alternative mech-
anism has also been proposed whereby phospho-Pak (Ser 293)
is able to autophosphorylate Ser 217/Ser 221 (Park et al., 2007).
In iIC-stimulated human neutrophils, Raf inhibition did not affect
Erk activity. Instead, Pak inhibition interfered with Mek and Erk
activation, in line with Pak-dependent Mek autophosphorylation
(Park et al., 2007).
In contrast to the short-term inhibition of Erk activation by both
Mek inhibitors (Figures 2M and 2P), at longer time points used for
the examination of apoptosis, tramatinib but not AZD6244 was
observed to be effective (Figure 6A; Figure S3). The Ras-Raf-
Mek-Erk pathway is known to rely on a series of positive and
negative feedback regulations that havebeenpainstakingly deci-
phered in cancer cells (reviewedbyCaunt et al., 2015). Tramatinib
belongs to a new class of ‘‘feedback buster’’ Mek inhibitors that,
in addition to inhibiting Mek, disrupt the conformation of the Mek
activation loop, interferingwith feedback-induced, Raf-mediated
phosphorylation ofMek, thereby reducing feedback-induced Erk
activation (Ishii et al., 2013). It is conceivable that Erk feedback
loops operate in non-transformed neutrophils even under situa-
tions where the Ras-Raf-Mek pathwaywould not normally apply.
Raf inhibition had no effect by itself, but it did when inhibition
occurred in combination with AZD6244-mediated inhibition of
Mek (Figure S3). One possibility is that, under the condition of
long-term stimulation, a Raf-dependent input was precipitated
because of triggering the negative feedback loop by Erk hypoac-
tivity following Mek inhibition with the AZD6244 compound.
In a second, unexpected twist, our work advocates that
Cdc42 rather than Rac is activated in a PI3K-dependent fashion
in iIC-stimulated neutrophils. There have been rare examples
of PI3K-dependent Cdc42 activation events (Aoki et al., 2004;
El-Sibai et al., 2007), but no PIP3 activated GEFs have been
identified yet. It will be fascinating to identify which GEF (and
potentially additional intermediate steps) are involved in this
reaction. It would also be interesting to identify whether PI3K-
dependent Cdc42 activation is restricted to neutrophils.Cell Reports 17, 374–386, October 4, 2016 381
Figure 7. PI3Kb/d Signaling Regulates iIC-Induced Neutrophil Functions Other Than Apoptosis
Peripheral blood-derived healthy donor neutrophils were pre-incubated with small-molecule inhibitors (LY294002, stable pan-PI3K inhibitor; TGX221, PI3Kb;
IC87114, PI3Kd; PF3758309, Pak; tramatinib, Mek; FR180204 and BVD523, Erk) or vehicle at 37C for 10 min as indicated prior to stimulation with 10 mg/mL iIC.
(A and B) Characterization of iIC-induced internal ROS production.
(A) The data (mean ± range) presented are from a representative experiment employing PI3K inhibitors of a total of three performed.
(B) Total light emissions (mean ±SEM) of inhibitor-treated cells expressed as percentage of the response obtainedwith stimulated control cells. Data were pooled
from a minimum of three separately conducted experiments.
(C) Cells were cultured for 12 hr, followed by analysis of cytokine release in the culture supernatants by ELISA. The data shownwere pooled from three separately
conducted experiments. *p < 0.05, **p < 0.01.
(D) Neutrophil surface CD62L was analyzed by flow cytometry. For ease of viewing, the mock-stimulated and iIC-stimulated histograms were copied into each
inhibitor treatment (black, basal cells; blue, iIC-stimulated cells; red, iIC-stimulated and inhibitor-treated cells). A representative experiment is presented from a
total of three separate experiments performed.
(E) A schematic of the non-canonical signaling pathway regulating apoptosis in iIC-stimulated human neutrophils (blue boxes). This unusual pathway regulates
Mek and Erk independently of Ras and Raf, instead using Cdc42 and Pak to regulate iIC-induced neutrophil apoptosis. Other functions are regulated by PI3Kb/
d employing diverging pathways (orange boxes).
See also Figure S4.
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Our work indicates that the unconventional PI3K signaling
pathway delineated here is pro-apoptotic, complementing previ-
ous findings that described iIC-induced neutrophil apoptosis
without elucidating the signaling pathway that regulates it (Gam-
berale et al., 1998; Ottonello et al., 2001; Schettini et al., 2002).
Although iIC-induced apoptosis has been shown to depend on
ROS production, our experiments demonstrate that apoptosis
and ROS production are regulated by distinct pathways
downstream of PI3K, suggesting that ROS production may be
required but not sufficient for iIC-induced apoptosis to occur.
Although it remains unclear whether there is a similar causal
relationship between other immune-complex-induced functions
that are regulated by PI3K (such as chemokine production) and
apoptosis, the fact that distinct pathways regulate apoptosis
and other effector functions may permit their pharmacological
‘‘uncoupling,’’ e.g., inhibiting apoptosis without affecting ROS
production or chemokine release.
There is already evidence for pro- and anti-apoptotic functions
of Erk (reviewed by Cagnol and Chambard, 2010). Our results
suggest that PI3K/Erk-dependent regulation of Bcl-2 family
members is required for iIC-induced pro-apoptotic effects. Erk
is known to regulate Bcl2 family members, and our data agree
with such a function in the context of iIC-induced neutrophil
apoptosis.
Although better known for its anti-apoptotic function via Akt,
PI3K has also been shown to have pro-apoptotic functions in
TNF-a-stimulated neutrophils (Geering et al., 2011). It is inter-
esting that neutropenia was one of the side effects reported
with the PI3Kd inhibitor idelalisib when administered in clinical
trials to leukemia/lymphoma patients who had failed previous
rounds of chemotherapy (Furman et al., 2014; Miller et al.,
2015). In our experiments, inhibiting PI3Kd did not drive
apoptosis of control neutrophils (Figure S2J). Furthermore, the
increased lifespan of neutrophils taken from chronic obstructive
pulmonary disease (COPD) patients during acute exacerbations
was also not affected by inhibition of PI3Ks (Juss et al., 2012).
One possibility is that the neutropenia observed with idelalisib
treatment may be due to effects on hematopoiesis and produc-
tion or release of neutrophils into the circulation rather than on
circulating neutrophils.
PI3K signaling holds a key role in controlling inflammation,
including in neutrophil-driven chronic autoinflammatory dis-
eases such as rheumatoid arthritis in which immune complexes
represent an important pathophysiological mechanism. The
recent development of genetically modified mice with altered
PI3K signaling in combination with isoform-selective small-
molecule inhibitors has led to a detailed understanding of PI3K
signaling in a range of mouse models of autoimmune diseases.
This has fed into the current focus on drug discovery surrounding
PI3K to target human chronic autoimmune disorders in the
clinical setting in addition to the important ongoing efforts in
the cancer field. Our work highlights that PI3K signaling is not
well conserved between mouse and human neutrophils, indi-
cating that understanding derived from themousemodels needs
to be interpreted with caution. In addition, given that the resolu-
tion of inflammation relies on the prompt induction of neutrophil
apoptosis and efferocytosis of apoptotic neutrophils (Lucas
et al., 2014; Poon et al., 2014; Rossi et al., 2006), our work hasimportant implications for approaches tomodulate inflammatory
disease by targeting PI3Kb/d. Under conditions where immune
complexes promote neutrophil apoptosis through the non-ca-
nonical pathway described here, inhibition of PI3Kb/d may act
to limit neutrophil clearance. In contrast, under conditions where
immune-complex-induced apoptosis is detrimental, for example
by exceeding the clearance capacity and thereby leading to
excess necrosis, inhibition of the pathway may be preferable.
EXPERIMENTAL PROCEDURES
Reagents
Unless indicated otherwise, all reagents were obtained fromSigma-Aldrich. All
reagents were of the highest available grade and lowest possible endotoxin
level. Tissue culture media and buffers were obtained from Life Technologies,
and dextran and Percoll were from GE Healthcare. The antibodies used were
as follows: b-actin (rabbit polyclonal) from Abcam; Bax (clone B-9) and Mcl1
(rabbit polyclonal) from Santa Cruz Biotechnology; phospho-Akt Thr 308
(clone L32A4), phospho-Akt Ser 473 (clone D9E biotinylated), phospho-Erk
Thr 202/Tyr 204 (clone E10), phospho-Mek1/2 Ser 217/221 (rabbit polyclonal),
phospho-p38 Thr 180/Tyr 182 (rabbit polyclonal), and phospho-Pak1 Ser 144
(rabbit polyclonal) from Cell Signaling Technology; and CD62L-PC5 conjugate
from Immunotech.
The inhibitors and final concentrations used were as follows: pan-PI3K,
wortmannin (50 nM), and LY2940002 (10 mM, used for prolonged inhibition
because wortmannin has a very short half-life in aqueous solutions); PI3Ka
and A66 (10 mM); PI3Kb and TGX221 (40 nM); PI3Kd and IC87114 (1 mM);
and PI3Kg, AS252424 (30 mM), and CZC24832 (10 mM) (all from Sigma); the
Raf inhibitor AZ628 (5 mM); the Mek inhibitors AZD6244 (1 mM) and trametinib
(1 mM); the Pak inhibitors PF3758309 (5 mM) and IPA3 (10 mM); the Erk inhibitor
FR180204 (10 mM); and BVD523 (5 mM) (all from Selleckchem).
Human Peripheral Blood Neutrophil Isolation
Neutrophils were isolated from healthy donor blood as described previously
(Lucas et al., 2013). Ethics approval was obtained from the local Lothian
Research Ethics Committee (approvals 08/S1103/38 and AMREC 15-HV-
013). Neutrophil purity was >95% as assessed by analysis of cytocentrifuge
preparations.
Isolation of Mouse Neutrophils
Mouse work was conducted under the control of the UK Home Office at the
University of Edinburgh and approved by the University of Edinburgh animal
welfare committee (PPL 60/4502). Mouse bone marrow-derived neutrophils
were purified from C57Bl/6 mice using a discontinuous Percoll gradients
as previously described (Gambardella et al., 2011). Neutrophil purity was
75%–80% as assessed by analysis of cytocentrifuge preparations. After
washing, neutrophils were resuspended in Dulbecco’s PBS with Ca2+ and
Mg2+, 1 g/L glucose, and 4 mM sodium bicarbonate (PBS2+).
Preparation of Immune Complexes
iICs (human serum albumin [HSA] and rabbit polyconal IgG to HSA) were pre-
pared in batches by titrating the point of equivalence between antigen and
antibody and monitoring the point of equivalence by monitoring the absor-
bance at 450 nM as described previously (Crockett-Torabi and Fantone,
1990; Fossati et al., 2002a). Any soluble immune complexes formed were dis-
carded prior to use in any experiment by repeated washing with PBS because
insoluble and soluble immune complexes trigger distinct responses in neutro-
phils (Fossati et al., 2002a). The lowest concentration of iICs required to trigger
a significant response was used for experiments (data not shown).
Indirect Assaying of Protein Kinase Activity
Peripheral blood neutrophils were pre-warmed for 5 min at 37C in PBS2+
before being incubated with inhibitors or vehicle. Pre-warmed stimuli were
gently mixed with the pre-warmed neutrophils in a test tube. To end the assay,
cells were pelleted and, after careful aspiration of the supernatant, lysed inCell Reports 17, 374–386, October 4, 2016 383
ice-cold lysis buffer (20 mM Tris-HCl [pH 7.5], 150 mM NaCl, 1 mM EDTA,
1 mM EGTA, 1% Triton X-100, 2.5 mM Na pyrophosphate, 1 mM b-glycero-
phosphate, 1 mM Na orthovanadate, 0.1 mM PMSF, and 10 mg/mL each of
antipain, aprotinin, pepstatin A, and leupeptin). After pelleting the detergent-
insoluble material, lysates were boiled with sample buffer prior to resolution
of proteins by SDS-PAGE, transfer to a polyvinylidene fluoride (PVDF) mem-
brane (Millipore), and immunoblotting with antibodies of interest. Because of
the strong proteolytic activities present in neutrophils, the numbers of experi-
mental samples handled in any one experiment were kept to a minimum.
Small GTPase Activity Assays
Ras, Rac, Cdc42, and Rho activities were determined by G-LISA (Cytoskel-
eton) essentially according to the manufacturer’s instruction, except that the
lysis buffer was supplemented with 7 mM diisopropyl fluorophosphate in addi-
tion to the standard antiprotease cocktail.
Assessment of Cell Viability and Apoptosis
Cellular changes associated with apoptosis of Diff-Quik-stained cytocentri-
fuge preparations were assessed by light microscopy. In addition, neutrophil
apoptosis and secondary necrosis were measured by flow cytometry (FACS
Calibur, BD Biosciences) of fluorescein isothiocyanate (FITC)-labeled annexin
V-stained (Roche) and propidium iodide-stained (Sigma) cells as described
previously (Lucas et al., 2013). Data were analyzed using Flowjo (Tree Star).
Chemoluminescence Detection of ROS
Internal ROS production was measured by chemoluminescence in a Synergy
H1 plate reader (BioTek Instruments) using luminescence-grade 96-well plates
(Nunc) in PBS2+ supplemented with 150 mM luminol but in the absence of
exogenous HRP. Following pre-incubation of neutrophils with inhibitors or
vehicle (DMSO), stimuli were added manually, and light emission was re-
corded immediately. Data output was in relative light units (RLU) per second.
Cytokine Release Assays
Following pre-incubation with inhibitors, neutrophils were stimulated as indi-
cated and cultured in round-bottom 96-well plates (Corning Life Sciences) in
RPMI 1640medium supplementedwith 10% autologous serum in a humidified
tissue culture incubator at 37Cand 5%CO2. Supernatants were harvested for
cytokine analysis by ELISA (R&D Systems) according to the manufacturer’s
instructions.
L-selectin Measurement
Surface L-selectin was determined by flow cytometry. Neutrophils were pre-
incubated with inhibitors or vehicle, stimulated with iICs, and cultured at
37C prior to incubation with FITC-conjugated antibody directed to L-selectin
and analysis on a FACSCalibur flow cytometer (BD Biosciences). Data were
analyzed using FlowJo software.
Statistical Analysis
For pairwise comparisons, where data met the assumptions for parametric
tests, two-tailed Student’s t tests were applied. Otherwise, the non-parametric
Mann-Whitney rank-sum test was used for pairwise comparisons. For multiple
comparisons, data were analyzed using Kruskal-Wallis one-way ANOVA on
ranks with Dunn post hoc test. For kinetic experiments, the area under the
graph was used for analysis. p values < 0.05 were considered statistically
significant.
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